Protagonist Therapeutics Inc PTGX.OQ PTGX.O is expected to show a fall in quarterly revenue when it reports results on May 5 (estimated) for the period ending March 31 2025
The Newark California California-based company is expected to report a 88.1% decrease in revenue to $30.444 million from $254.95 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Protagonist Therapeutics Inc is for a loss of 17 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 12.2% in the last three months.
Wall Street's median 12-month price target for Protagonist Therapeutics Inc is $70.00, above its last closing price of $45.51.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | 0.63 | 0.32 | 1.98 | Beat | 516.6 |
Sep. 30 2024 | -0.58 | -0.61 | -0.54 | Beat | 11.1 |
Jun. 30 2024 | -0.57 | -0.60 | -0.50 | Beat | 16.9 |
Mar. 31 2024 | 0.54 | 1.19 | 3.26 | Beat | 173.1 |
Dec. 31 2023 | 0.03 | -0.03 | 0.44 | Beat | 1,425.3 |
Sep. 30 2023 | -0.70 | -0.69 | -0.58 | Beat | 16.4 |
Jun. 30 2023 | -0.65 | -0.65 | -0.68 | Missed | -5 |
Mar. 31 2023 | -0.77 | -0.73 | -0.67 | Beat | 7.8 |
This summary was machine generated May 5 at 21:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)